IDEXX Laboratories delivered a solid QQ3 2025 performance with meaningful top-line growth and durable profitability across its diversified portfolio of companion animal diagnostics, veterinary reference laboratories, and water quality testing. Revenue reached $1.105 billion, up 13.3% year over year, while gross profit was $683.354 million, yielding a gross margin of 61.8%. Operating income stood at $354.846 million (operating margin of 32.1%), and EBITDA was $228.73 million (EBITDA margin ~20.7%). Net income was $274.61 million, implying a net margin of about 24.8%. These metrics reflect strong demand for IDEXX’s core consumables and instruments, coupled with a favorable product mix and pricing power in a high-penetration, high-margin diagnostics business.
A notable data anomaly appears in the reported earnings per share figure for QQ3 2025, which shows an EPS of -6.64 (diluted -6.59) despite a positive net income and a reasonable share base. The discrepancy suggests a data error in the provided dataset or a timing/formatting inconsistency prior to the quarterly reconciliation; readers should verify against the official SEC filing. Excluding the EPS inconsistency, the quarter reinforces IDEXX’s healthy profitability trajectory and its ability to translate mid-teens revenue growth into robust earnings gains. Management commentary (not included in the provided data) typically emphasizes durable demand in companion animal diagnostics, ongoing investments in R&D and practice-management services, and expansion of service platforms, all of which support a constructive longer-term outlook.
Overall, IDEXX remains well-positioned within the healthcare diagnostics landscape, leveraging a diversified, recurring-revenue framework, strong pricing power, and an expansive global footprint. The primary near-term uncertainties relate to the absence of explicit forward guidance in the provided materials and potential currency and macro headwinds, which will be important to monitor as the company progresses through the balance of 2025.